Otsuka Holdings (4578.T)

Executive Summary

Otsuka Holdings is a Japanese global healthcare conglomerate with a strong presence in central nervous system (CNS) therapeutics, pharmaceuticals, and nutraceuticals. The company's flagship CNS portfolio, including drugs for schizophrenia and bipolar disorder, and its innovative formulation technologies position it as a key player in psychiatry and neurology markets worldwide. Otsuka operates in over 80 countries and has a market capitalization of approximately $5.7 trillion yen (as of early 2026). Despite facing generic competition for some key products, the company continues to invest in R&D, focusing on next-generation CNS therapies including digital therapeutics and treatments for neurodegenerative diseases. Otsuka's diversified business across pharma and nutraceuticals provides stability, while its pipeline holds potential for growth in high-need areas.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on AVP-786 for Alzheimer's agitation55% success
• Q4 2026Phase 3 data readout for DSP-2342 in depression50% success
• Q1 2027Japan regulatory submission for digital therapeutic OTX-200170% success